Actualizado 22/03/2007 17:55
- Comunicado -

Eisai to Acquire Morphotek (y 2)

About Libradoma(TM)

The Libradoma(TM) technology process utilizes Human MORPHODOMA(R) and other propriety technologies to generate libraries potentially comprised of thousands of hybridomas that can be rapidly screened using high-throughput robotics to identify hybridomas expressing human antibodies with target affinity profiles.

For further media information in Europe, please contact: Andrew Day, Eisai Europe Ltd, +44-(0)208-600-1400 Andrew_Day@eisai.net or Eisai Contact Information, Corporate Communications Department, Eisai Co., Ltd., +81-3-3817-5120, webmaster@eisai.co.jp, ECA Contact Information, Cathy Pollini, Corporate Planning and Communications, Eisai Inc., +1-201-746-2052, cathy_pollini@eisai.com, Morphotek Contact Information, Nicholas Nicolaides, President & CEO, Morphotek Inc., +1-610-423-6100, nicolaides@morphotek.com

Contenido patrocinado